Provided by Tiger Trade Technology Pte. Ltd.

Global X Genomics & Biotechnology ETF

69.62
+0.84101.22%
Post-market: 69.44-0.1810-0.26%19:49 EDT
Volume:16.76K
Turnover:1.16M
Market Cap:101.97M
PE:- -
High:69.71
Open:69.50
Low:68.72
Close:68.78
52wk High:71.10
52wk Low:40.17
Shares:1.46M
Float Shares:1.46M
Volume Ratio:0.34
T/O Rate:1.14%
Dividend:0.65
Dividend Rate:0.93%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Transgene Jumps 20% on Positive Cancer Vaccine Data in Early Trial

Reuters
·
Sep 03

uniQure seeks accelerated approval for Huntington’s gene therapy

TIPRANKS
·
Sep 02

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

GlobeNewswire
·
Sep 02

Guardant Health Price Target Maintained with a $195.00/Share by BTIG

Dow Jones
·
Sep 02

Moderna Plans Private Placement of $2 Billion Convertible Senior Notes Due 2032

Reuters
·
Sep 02

Moderna Inc. Stock Advances 9.9%, Outperforms Peers

Dow Jones
·
Sep 02

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Guardant Health (GH)

TIPRANKS
·
Sep 02

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Sep 02

Guardant Health Shield Blood Test Wins Carelon Coverage for Colorectal Cancer Screening

Reuters
·
Sep 01

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

GlobeNewswire
·
Sep 01

Moderna to Present at Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 01

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

TIPRANKS
·
Sep 01

Natera announces publication of new data in Blood Neoplasia on Signatera

TIPRANKS
·
Sep 01

Top 10 Best-Performing US Stocks in August: Moderna Surges 156%, Palantir Leads AI Software Stocks

TradingKey
·
Sep 01

Circio boosts circVec gene therapy data and secures funding runway to 2030

TIPRANKS
·
Sep 01

Cboe data suggests bullish flow in Moderna with shares up 0.71%

TIPRANKS
·
Sep 01

Moderna Stock (MRNA) Was the Best Performer in August

TIPRANKS
·
Sep 01

CytoDyn Net Loss Widens to $42.7 Million in FY26

Reuters
·
Aug 31

Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.
·
Aug 30

August Turmoil: Bessent's Intervention and the Quiet Reveal of Policy's Hidden Hand

Deep News
·
Aug 30